S02.6 · Healthcare & Life Sciences
A $180-200B research-enablement market split between concentrated instrument makers and fragmented, project-based CROs.
Life sciences tools, instruments and CROs — the research-enablement layer sitting upstream of drug development — is a combined $180-200B market in 2025 (life science instruments and reagents at roughly $100-110B per Precedence Research; CRO services at roughly $80-90B per Grand View Research), growing 7-9% forward on biologics, cell-and-gene-therapy R&D outsourcing and genomics tooling demand. The combined figure flatters the weaker half. One side is a concentrated, high-margin instruments franchise; the other is a fragmented, project-based CRO services business with far more working-capital exposure, and the two should not be underwritten the same way.
Historical growth of 6-8% steps up to a projected 7-9% forward. Revenue concentrates in US and EU biopharma R&D hubs, while CRO delivery capacity is increasingly built out in India and China for cost arbitrage. Concentration diverges by half: the tools side sits with Thermo Fisher, Danaher, Agilent and Illumina; the CRO side is more fragmented, with IQVIA and Icon leading a long tail of niche and therapeutic-area-specialist CROs.
Component and reagent suppliers sit upstream; biopharma sponsors and academic institutions downstream. Tools carry 55-65% gross margins on a capital-equipment-plus-consumables model — closer to the medtech pattern than to anything else nearby. CROs run 10-20% EBITDA on project-based and milestone billing, a structure that ties working capital to biotech funding cycles: when venture funding for clinical-stage biotech slows, CRO bookings show it directly.
Trial-site selection, protocol design and data monitoring — the clinical-operations headcount that has historically been the largest cost component in running a CRO — are all moving to agentic AI. The cost story is not the important one, though. The CRO's manual-monitoring moat is eroding, and AI-native trial platforms are arriving as direct competitors to incumbent CROs rather than as tools incumbents simply adopt. That is a genuine new-entrant threat, not a productivity story.
Adjacency moves show each half defending or expanding on its own logic. Tools majors are crossing into diagnostics and bioprocessing, adjacent to CDMO capacity — new spend, expansionary. CROs are crossing into real-world evidence and regulatory consulting — also expansionary, chasing data-analytics revenue with a different margin profile than project-based trial execution. Therapeutic-area CRO scale-up is the defensive move, a hedge against the volatility of the biotech funding cycles that drive project volume. Trial data management automation is already underway; AI-run adaptive trials sit on a 2-5 year horizon.